Precision drug development in ROS1-positive lung cancer

Colin Hardin, Feng Wang, Haiying Cheng

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: The treatment paradigm of non-small cell lung cancer (NSCLC) continues to evolve with the advent of broadened molecularly-targeted approaches. Similar to activating EGFR mutations and ALK rearrangements, ROS1 translocations define a distinct molecular subtype of NSCLC. ROS1 forms fusion products with a series of partners, leading to oncogenesis. Areas covered: This review will discuss key ROS1-fusion related downstream pathways and diagnostic techniques for detection of ROS1 rearrangements. Crizotinib, an inhibitor of MET/ALK/ROS1, has been approved as a targeted treatment for ROS1 positive lung cancer. Moreover, we will address the main resistance mechanisms to crizotinib, including development of secondary ROS1 mutations (such as G2032R and L2026M), activation of bypass signaling pathways (including EGFR and KRAS) and limitations in central nervous system penetrance. We will also review emerging therapies in ROS1 positive NSCLC, including cabozantinib, lorlatinib, entrectinib, and ceritinib. Expert commentary: Targeted therapy in ROS1 positive NSCLC has resulted in improved clinical outcomes compared with traditional chemotherapy. Thus, it is essential to screen for ROS1 fusions in NSCLC patients. Continued investigations should focus on improving understanding and identification of resistance mechanisms upon disease progression via repeat tissue or liquid biopsy, with the ultimate goal to tailor subsequent treatment to specific aberrations.

Original languageEnglish (US)
Pages (from-to)99-107
Number of pages9
JournalExpert Review of Precision Medicine and Drug Development
Volume2
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Pharmaceutical Preparations
Therapeutics
Mutation
Penetrance
Disease Progression
Carcinogenesis
Central Nervous System
Biopsy
Drug Therapy
crizotinib

Keywords

  • Adenocarcinoma
  • Crizotinib
  • Non-small cell lung cancer
  • Resistance
  • ROS1

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Precision drug development in ROS1-positive lung cancer. / Hardin, Colin; Wang, Feng; Cheng, Haiying.

In: Expert Review of Precision Medicine and Drug Development, Vol. 2, No. 2, 01.01.2017, p. 99-107.

Research output: Contribution to journalReview article

@article{a5a548edb9dd444cae91f8cb16f2c6ff,
title = "Precision drug development in ROS1-positive lung cancer",
abstract = "Introduction: The treatment paradigm of non-small cell lung cancer (NSCLC) continues to evolve with the advent of broadened molecularly-targeted approaches. Similar to activating EGFR mutations and ALK rearrangements, ROS1 translocations define a distinct molecular subtype of NSCLC. ROS1 forms fusion products with a series of partners, leading to oncogenesis. Areas covered: This review will discuss key ROS1-fusion related downstream pathways and diagnostic techniques for detection of ROS1 rearrangements. Crizotinib, an inhibitor of MET/ALK/ROS1, has been approved as a targeted treatment for ROS1 positive lung cancer. Moreover, we will address the main resistance mechanisms to crizotinib, including development of secondary ROS1 mutations (such as G2032R and L2026M), activation of bypass signaling pathways (including EGFR and KRAS) and limitations in central nervous system penetrance. We will also review emerging therapies in ROS1 positive NSCLC, including cabozantinib, lorlatinib, entrectinib, and ceritinib. Expert commentary: Targeted therapy in ROS1 positive NSCLC has resulted in improved clinical outcomes compared with traditional chemotherapy. Thus, it is essential to screen for ROS1 fusions in NSCLC patients. Continued investigations should focus on improving understanding and identification of resistance mechanisms upon disease progression via repeat tissue or liquid biopsy, with the ultimate goal to tailor subsequent treatment to specific aberrations.",
keywords = "Adenocarcinoma, Crizotinib, Non-small cell lung cancer, Resistance, ROS1",
author = "Colin Hardin and Feng Wang and Haiying Cheng",
year = "2017",
month = "1",
day = "1",
doi = "10.1080/23808993.2017.1322899",
language = "English (US)",
volume = "2",
pages = "99--107",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Precision drug development in ROS1-positive lung cancer

AU - Hardin, Colin

AU - Wang, Feng

AU - Cheng, Haiying

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: The treatment paradigm of non-small cell lung cancer (NSCLC) continues to evolve with the advent of broadened molecularly-targeted approaches. Similar to activating EGFR mutations and ALK rearrangements, ROS1 translocations define a distinct molecular subtype of NSCLC. ROS1 forms fusion products with a series of partners, leading to oncogenesis. Areas covered: This review will discuss key ROS1-fusion related downstream pathways and diagnostic techniques for detection of ROS1 rearrangements. Crizotinib, an inhibitor of MET/ALK/ROS1, has been approved as a targeted treatment for ROS1 positive lung cancer. Moreover, we will address the main resistance mechanisms to crizotinib, including development of secondary ROS1 mutations (such as G2032R and L2026M), activation of bypass signaling pathways (including EGFR and KRAS) and limitations in central nervous system penetrance. We will also review emerging therapies in ROS1 positive NSCLC, including cabozantinib, lorlatinib, entrectinib, and ceritinib. Expert commentary: Targeted therapy in ROS1 positive NSCLC has resulted in improved clinical outcomes compared with traditional chemotherapy. Thus, it is essential to screen for ROS1 fusions in NSCLC patients. Continued investigations should focus on improving understanding and identification of resistance mechanisms upon disease progression via repeat tissue or liquid biopsy, with the ultimate goal to tailor subsequent treatment to specific aberrations.

AB - Introduction: The treatment paradigm of non-small cell lung cancer (NSCLC) continues to evolve with the advent of broadened molecularly-targeted approaches. Similar to activating EGFR mutations and ALK rearrangements, ROS1 translocations define a distinct molecular subtype of NSCLC. ROS1 forms fusion products with a series of partners, leading to oncogenesis. Areas covered: This review will discuss key ROS1-fusion related downstream pathways and diagnostic techniques for detection of ROS1 rearrangements. Crizotinib, an inhibitor of MET/ALK/ROS1, has been approved as a targeted treatment for ROS1 positive lung cancer. Moreover, we will address the main resistance mechanisms to crizotinib, including development of secondary ROS1 mutations (such as G2032R and L2026M), activation of bypass signaling pathways (including EGFR and KRAS) and limitations in central nervous system penetrance. We will also review emerging therapies in ROS1 positive NSCLC, including cabozantinib, lorlatinib, entrectinib, and ceritinib. Expert commentary: Targeted therapy in ROS1 positive NSCLC has resulted in improved clinical outcomes compared with traditional chemotherapy. Thus, it is essential to screen for ROS1 fusions in NSCLC patients. Continued investigations should focus on improving understanding and identification of resistance mechanisms upon disease progression via repeat tissue or liquid biopsy, with the ultimate goal to tailor subsequent treatment to specific aberrations.

KW - Adenocarcinoma

KW - Crizotinib

KW - Non-small cell lung cancer

KW - Resistance

KW - ROS1

UR - http://www.scopus.com/inward/record.url?scp=85054823190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054823190&partnerID=8YFLogxK

U2 - 10.1080/23808993.2017.1322899

DO - 10.1080/23808993.2017.1322899

M3 - Review article

VL - 2

SP - 99

EP - 107

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 2

ER -